Cardiovascular Diabetology (Mar 2024)

Protective effects of imeglimin on the development of atherosclerosis in ApoE KO mice treated with STZ

  • Junpei Sanada,
  • Tomohiko Kimura,
  • Masashi Shimoda,
  • Yuichiro Iwamoto,
  • Hideyuki Iwamoto,
  • Kazunori Dan,
  • Yoshiro Fushimi,
  • Yukino Katakura,
  • Yuka Nogami,
  • Yoshiko Shirakiya,
  • Yuki Yamasaki,
  • Tomoko Ikeda,
  • Shuhei Nakanishi,
  • Tomoatsu Mune,
  • Kohei Kaku,
  • Hideaki Kaneto

DOI
https://doi.org/10.1186/s12933-024-02189-z
Journal volume & issue
Vol. 23, no. 1
pp. 1 – 10

Abstract

Read online

Abstract Background Imeglimin is a new anti-diabetic drug which promotes insulin secretion from pancreatic β-cells and reduces insulin resistance in insulin target tissues. However, there have been no reports examining the possible anti-atherosclerotic effects of imeglimin. In this study, we investigated the possible anti-atherosclerotic effects of imeglimin using atherosclerosis model ApoE KO mice treated with streptozotocin (STZ). Methods ApoE KO mice were divided into three groups: the first group was a normoglycemic group without injecting STZ (non-DM group, n = 10). In the second group, mice were injected with STZ and treated with 0.5% carboxymethyl cellulose (CMC) (control group, n = 12). In the third group, mice were injected with STZ and treated with imeglimin (200 mg/kg, twice daily oral gavage, n = 12). We observed the mice in the three groups from 10 to 18 weeks of age. Plaque formation in aortic arch and expression levels of various vascular factors in abdominal aorta were evaluated for each group. Results Imeglimin showed favorable effects on the development of plaque formation in the aortic arch in STZ-induced hyperglycemic ApoE KO mice which was independent of glycemic and lipid control. Migration and proliferation of vascular smooth muscle cells and infiltration of macrophage were observed in atherosclerotic lesions in STZ-induced hyperglycemic ApoE KO mice, however, which were markedly reduced by imeglimin treatment. In addition, imeglimin reduced oxidative stress, inflammation and inflammasome in hyperglycemic ApoE KO mice. Expression levels of macrophage makers were also significantly reduced by imeglimin treatment. Conclusions Imeglimin exerts favorable effects on the development of plaque formation and progression of atherosclerosis.

Keywords